The history of Viagra presents a complex case for stakeholders in the medicinal sector. While initially a tremendous success, producing huge profits, the exclusivity lapse and the subsequent arrival of generic versions have significantly impacted earnings. This poses questions about the long-term profitability of similar medication innovations and